Estradiol transdermal micro patch - Noven Pharmaceuticals

Drug Profile

Estradiol transdermal micro patch - Noven Pharmaceuticals

Alternative Names: Estradot; Minivelle; Vivelle-Dot

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Noven Pharmaceuticals
  • Developer Novartis; Noven Pharmaceuticals
  • Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Atrophic vaginitis; Menopausal syndrome; Postmenopausal osteoporosis; Primary ovarian insufficiency; Vasomotor symptoms

Most Recent Events

  • 07 Nov 2017 Noven Pharmaceuticals initiates litigation against Alvogen over ANDA submission in USA
  • 05 May 2015 Noven Pharmaceuticals and Hisamitsu Pharmaceutical filed first-to-file patent-challenge lawsuit relating to the generic version of Minivelle® in the US against Mylan N.V. and its subsidiaries
  • 18 Feb 2015 Launched for Postmenopausal osteoporosis (Prevention) in the US (Transdermal, Minivelle® 0.025 mg/day)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top